US OptionsDetailed Quotes
INDV250417P20000
- 0.00
- 0.000.00%
15min DelayTrading Apr 16 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover0.01%IV-122.47%PremiumApr 17, 2025Expiry Date11.01Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-1.0000Delta0.0000Gamma0.82Leverage Ratio0.0000Theta0.0000Rho-0.82Eff Leverage0.0000Vega
Indivior Stock Discussion
Game-Changing OUD Treatment Update: SUBLOCADE Now Offers 1-Hour Start Protocol
Unexpected FDA Delay: Indivior's SUBLOCADE Label Changes Face Setback Despite Clean Review
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance.
• Group now sees lower than expected Q3 2024 and FY 2024 SUBLOCADE net revenue (NR) from a combination of faster initial adoption among treatment providers of the...
No comment yet